8 unchanged sentences
None of the underwriting discounts and commissions or offering expenses were incurred or paid, directly or indirectly, to directors or officers of ours or their associates or to persons owning 10% or more of our common stock or to any of our affiliates.
−Removed: As of June 30, 2020, we have used approximately $33.7 million of net offering proceeds primarily for commercialization of OCS Lung, research and development, and general corporate purposes.
+Added: As of September 30, 2020, we have used approximately $40.3 million of net offering proceeds primarily for commercialization of OCS Lung, research and development, and general corporate purposes.
We are holding a significant portion of the remaining net proceeds in money market funds, U.S.
1 unchanged sentence
government agency bonds.
−Removed: There has been no m aterial change in our planned use of the net proceeds from the IPO as described in the final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act, with the SEC, on May 2, 2019 .
−Removed: Omnibus Amendment #2 to Lease, dated as of June 1, 2020, by and among the Company and Whetstone 200 Minuteman Park, LLC and Whetstone 30 Minuteman Park, LLC
−Removed: Promissory Note, dated as of April 20, 2020 (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 8-K (File No.
−Removed: 001-38891) filed with the SEC on April 24, 2020)
−Removed: Second Amendment to Credit Agreement, dated as of April 23, 2020, by and among by and among TransMedics, Inc., TransMedics Group, Inc., TransMedics, B.V., and Orbimed Royalty Opportunities II, LP (incorporated by reference to Exhibit 10.2 to the Registrant’s Form 8-K (File No.
−Removed: 001-38891) filed with the SEC on April 24, 2020)
−Removed: Amendment to Executive Retention Agreement, dated as of April 10, 2020, by and between TransMedics, Inc.
−Removed: and Stephen Gordon (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 8-K (File No.
−Removed: 001-38891) filed with the SEC on April 13, 2020)
+Added: There has been no material change in our planned use of the net proceeds from the IPO as described in the final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act, with the SEC, on May 2, 2019 .
Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
14 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: August 7, 2020
+Added: November 6, 2020
TRANSMEDICS GROUP, INC.
4 unchanged sentences
(Principal Executive Officer)
−Removed: August 7, 2020
+Added: November 6, 2020
/s/ Stephen Gordon
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.